profit from every $100 of sales.
$0$100
Biogen
$250.48-1.15% today
+55.1% in 1 year
1-year low $161.481-year high $254.87
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $28.64 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Biogen sold, what it kept, and what it did with the cash.
Sales went from $10.2 billion in 2022 to $9.89 billion in 2025, with $1.29 billion of profit last year.
SalesProfit
Biogen vs. similar companies
Biogen grows the slowest of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Biogen | 28.6× · Fair price | ||
 Eli Lilly | 61.6× · Very expensive | ||
 Johnson & Johnson | 25.5× · Fair price | ||
 AbbVie | 123.2× · Very expensive | ||
 Roche | 25.7× · Fair price |
AI analysis
An AI analyst reads Biogen's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 13,445 | 10,982 | 10,173 | 9,836 | 9,676 | 9,891 | |
| 11,639 | 8,872 | 7,895 | 7,302 | 7,366 | 7,486 | |
| – | – | 2,902 | 1,848 | 2,280 | 2,469 | |
| 5,727 | 2,487 | 4,357 | 2,039 | 2,830 | 2,604 | |
| 4,001 | 1,556 | 3,047 | 1,161 | 1,632 | 1,293 | |
| 24.80 | 10.40 | 20.87 | 7.97 | 11.18 | 8.79 | |
| 86.6% | 80.8% | 77.6% | 74.2% | 76.1% | 75.7% | |
| – | – | 28.5% | 18.8% | 23.6% | 25.0% | |
| 29.8% | 14.2% | 29.9% | 11.8% | 16.9% | 13.1% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 24,619 | 23,877 | 24,554 | 26,845 | 28,049 | 29,440 |
| Cash | 1,331 | 2,261 | 3,419 | 1,050 | 2,375 | 3,009 |
| Total debt | 7,911 | 6,694 | 6,614 | 7,338 | 6,630 | 6,577 |
| Total liabilities | 13,933 | 12,918 | 11,166 | 12,045 | 11,333 | 11,183 |
| 10,686 | 10,960 | 13,398 | 14,799 | 16,716 | 18,257 | |
| 161 | 150 | 146 | 146 | 146 | 147 | |
| 22.4% | 8.9% | 15.2% | 5.5% | 7.3% | 5.8% | |
| 37.4% | 14.2% | 22.7% | 7.8% | 9.8% | 7.1% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 4,230 | 3,640 | 1,384 | 1,547 | 2,876 | 2,205 | |
| – | – | 243 | 311 | 360 | 235 | |
| – | – | 1,141 | 1,236 | 2,516 | 1,969 | |
| Dividends paid | – | – | – | – | – | – |
| 6,679 | 1,800 | 750 | 0 | 0 | – | |
| 198 | 239 | 254 | 264 | 291 | 291 |
Valuation
- 28.6×
- 17.0×
- –
- 1.6×
- 3.7×
- 18.8×
- 15.6×
- 5.3%
- 3.5%
- 0.0%
Profitability
- 75.7%
- 25.0%
- 13.1%
- 28.3%
- 5.4%
- 8.2%
- 7.5%
- 4.7%
- 5.8%
- 20.1%
Growth
- −6.0%
- −18.7%
- −18.5%
- –
- −0.4%
Financial health
- 1.1×
- 0.35
- 22.3%
- 5.6×
- 3.06
- 2.41
- 0.33
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 50%of 952
Top 15%of 883
Bottom 48%of 576
Bottom 8%of 870
Top 20%of 985
What analysts expect
- Average price target
- $211.42
- Range
- $143.00 – $260.00
- 22 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 29, 2026 | 3.57 | 2.95 | +21.0% |
| Feb 6, 2026 | 1.99 | 1.63 | +22.1% |
| Oct 30, 2025 | 4.81 | 3.88 | +24.0% |
| Jul 31, 2025 | 5.47 | 3.90 | +40.3% |
| May 1, 2025 | 3.02 | 2.90 | +4.1% |
| Feb 12, 2025 | 3.44 | 3.43 | +0.3% |
| Oct 30, 2024 | 4.08 | 3.77 | +8.2% |
| Aug 1, 2024 | 5.28 | 4.07 | +29.7% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
52No pass
Benjamin Graham
68Pass
Philip Fisher
51No pass
Peter Lynch
25No pass
Joel Greenblatt
17No pass
Charlie Munger
52No pass
Terry Smith
51No pass
Questions about Biogen
Is Biogen a good stock to buy?
A solid business at a fair price. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Biogen AI analysis
What does Biogen do?
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. It is in Drug Manufacturers - General, based in Cambridge, MA, United States, with 7,500 employees.
Does Biogen pay a dividend?
No. Biogen does not pay a dividend at the moment.
Is Biogen stock halal?
Yes. Biogen passes our halal screen: its business is permitted and its debt is 18% of its market value, under the 30% limit. How we check
How has Biogen stock done over the past year?
Up 55.1% over the past twelve months, to $250.48. It traded between $161.48 and $254.87, close to its high.
Who are Biogen's competitors?
The largest listed companies in the same industry are Eli Lilly, Johnson & Johnson, AbbVie and Roche. The peers table on this page compares their profit, growth and price with Biogen's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.